Back to Parkinsons Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03361865

NCT03361865
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with advanced, inoperable, or spread (metastatic) bladder cancer or cancer of the renal pelvis, ureter, or urethra, confirmed by a lab test on a tissue or cell sample.
  • Your cancer can be measured on scans using standard guidelines (called RECIST v1.1).
  • You have been assessed as not suitable to receive a chemotherapy drug called cisplatin, based on specific trial criteria (confirm with trial site).
  • You are able to provide a tissue sample — either from a stored biopsy or a new biopsy — from a tumor that has not previously been treated with radiation, for a specific protein test (PD-L1).
  • You have not previously had chemotherapy treatment for your advanced, inoperable, or metastatic urothelial cancer.
  • Your general health and ability to carry out daily activities falls within an acceptable range on a standard scale (called ECOG 0, 1, or 2), assessed within 14 days before joining the trial.
  • Your organs (such as kidneys, liver, and bone marrow) are functioning well enough to meet the trial's specific requirements (confirm with trial site).

Who may not be able to join:

  • Your cancer could still be treated with local treatments aimed at curing it (such as surgery or radiation).
  • You have another cancer that is currently growing or has needed active treatment within the last 3 years.
  • You have active cancer that has spread to the brain or the lining around the brain, unless previously treated brain spread has been stable for at least 4 weeks, you are clinically stable, and you have not needed steroid medication for at least 14 days before starting the trial.
  • You have an autoimmune disease (where your immune system attacks your own body) that has needed medication or treatment in the past 2 years.
  • You have a known history of HIV infection.
  • You have a known history of active hepatitis B or active hepatitis C (specific blood tests will be needed to confirm this).
  • You have a history of a stomach or bowel condition that might affect how your body absorbs a tablet or capsule form of medication.
  • You have an abnormal heart tracing (ECG) that the trial doctor considers to be medically significant.
  • You are taking certain medications or have had certain previous treatments that are not allowed under the trial's rules (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Incyte Corporation
Registry
clinicaltrials_gov
Start date
4 December 2017
Est. completion
9 August 2018

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇫🇷 France 🇩🇪 Germany 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇵🇱 Poland 🇷🇺 Russia 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov